1 line
No EOL
19 KiB
Text
1 line
No EOL
19 KiB
Text
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T17:29:18Z","timestamp":1698514158243},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018854","name":"Sirtex Medical","doi-asserted-by":"publisher"},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n <jats:title>Objectives<\/jats:title>\n <jats:p>To identify clinical and imaging parameters associated with progression of non-hypervascular hepatobiliary phase hypointense lesions during follow-up in patients who received treatment for hepatocellular carcinoma.<\/jats:p>\n <\/jats:sec><jats:sec>\n <jats:title>Methods<\/jats:title>\n <jats:p>A total of 67 patients with 106 lesions were identified after screening 538 patients who underwent gadoxetic acid\u2013enhanced MRI within the SORAMIC trial. All patients were allocated to the trial treatment according to the trial scheme, and 61 of 67 patients received systemic treatment with sorafenib (either alone or combined with locoregional therapies) during the trial period. Follow-up images after treatment according to trial scheme were reviewed for subsequent hypervascularization or > 1 cm size increase. The correlation between progression and several imaging and clinical parameters was assessed using univariable and multivariable analyses.<\/jats:p>\n <\/jats:sec><jats:sec>\n <jats:title>Results<\/jats:title>\n <jats:p>On a median 178 (range, 48\u20131072) days follow-up period, progression was encountered in 18 (16.9%) lesions in 12 (17.9%) patients. In univariable analysis size > 12.6 mm (<jats:italic>p<\/jats:italic> = 0.070), ECOG-PS (<jats:italic>p<\/jats:italic> = 0.025), hypointensity at T1-weighted imaging (<jats:italic>p<\/jats:italic> = 0.028), hyperintensity at T2-weighted imaging (<jats:italic>p<\/jats:italic> < 0.001), hyperintensity at DWI images (<jats:italic>p<\/jats:italic> = 0.007), and cirrhosis (<jats:italic>p<\/jats:italic> = 0.065) were correlated with progression during follow-up. Hyperintensity at T2 images (<jats:italic>p<\/jats:italic> = 0.011) was an independent risk factor for progression in multivariable analysis, as well as cirrhosis (<jats:italic>p<\/jats:italic> = 0.033) and ECOG-PS (<jats:italic>p<\/jats:italic> = 0.030).<\/jats:p>\n <\/jats:sec><jats:sec>\n <jats:title>Conclusions<\/jats:title>\n <jats:p>Non-hypervascular hepatobiliary phase hypointense lesions are associated with subsequent progression after treatment in patients with HCC. T2 hyperintensity, diffusion restriction, cirrhosis, and higher ECOG-PS could identify lesions with increased risk. These factors should be considered for further diagnostic evaluation or treatment of such lesions.<\/jats:p>\n <\/jats:sec><jats:sec>\n <jats:title>Key Points<\/jats:title>\n <jats:p><jats:italic>\u2022 Non-hypervascular hepatobiliary phase hypointense lesions have considerable risk of progression in patients with hepatocellular carcinoma receiving treatment.<\/jats:italic><\/jats:p>\n <jats:p><jats:italic>\u2022 T2 hyperintensity, cirrhosis, ECOG-PS, and hyperintensity at DWI are associated with increased risk of progression.<\/jats:italic><\/jats:p>\n <jats:p><jats:italic>\u2022 Non-hypervascular hepatobiliary phase hypointense lesions should be considered in the decision-making process of locoregional therapies, especially in the presence of these risk factors.<\/jats:italic><\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00330-022-09000-1","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T06:04:49Z","timestamp":1658815489000},"page":"493-500","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression"],"prefix":"10.1007","volume":"33","author":[{"given":"Osman","family":"\u00d6cal","sequence":"first","affiliation":[]},{"given":"Christoph J.","family":"Zech","sequence":"additional","affiliation":[]},{"given":"Matthias P.","family":"Fabritius","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Loewe","sequence":"additional","affiliation":[]},{"given":"Otto","family":"van Delden","sequence":"additional","affiliation":[]},{"given":"Vincent","family":"Vandecaveye","sequence":"additional","affiliation":[]},{"given":"Bernhard","family":"Gebauer","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Sengel","sequence":"additional","affiliation":[]},{"given":"Irene","family":"Bargellini","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Iezzi","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Benito","sequence":"additional","affiliation":[]},{"given":"Maciej","family":"Pech","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Malfertheiner","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[]},{"given":"Max","family":"Seidensticker","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"9000_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/hep.21966","volume":"47","author":"A Forner","year":"2008","unstructured":"Forner A, Vilana R, Ayuso C et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:97\u2013104","journal-title":"Hepatology"},{"key":"9000_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.crad.2020.12.007","volume":"76","author":"CGD Clarke","year":"2021","unstructured":"Clarke CGD, Albazaz R, Smith CR et al (2021) Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation. Clin Radiol 76:333\u2013341","journal-title":"Clin Radiol"},{"key":"9000_CR3","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1007\/s00330-020-07468-3","volume":"31","author":"SH Hwang","year":"2021","unstructured":"Hwang SH, Park MS, Park S, Lim JS, Kim SU, Park YN (2021) Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol 31:4492\u20134503","journal-title":"Eur Radiol"},{"key":"9000_CR4","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1007\/s00330-020-06881-y","volume":"30","author":"SK Jeon","year":"2020","unstructured":"Jeon SK, Lee JM, Joo I, Yoo J, Park JY (2020) Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. Eur Radiol 30:4762\u20134771","journal-title":"Eur Radiol"},{"key":"9000_CR5","doi-asserted-by":"publisher","unstructured":"Min JH, Kim JM, Kim YK et al (2021) EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC. Liver Int. https:\/\/doi.org\/10.1111\/liv.15012","DOI":"10.1111\/liv.15012"},{"key":"9000_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1148\/radiol.2020192275","volume":"296","author":"I Joo","year":"2020","unstructured":"Joo I, Kim SY, Kang TW et al (2020) Radiologic-pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced MRI: a multicenter study. Radiology 296:335\u2013345","journal-title":"Radiology"},{"key":"9000_CR7","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1136\/gutjnl-2017-315384","volume":"67","author":"M Renzulli","year":"2018","unstructured":"Renzulli M, Biselli M, Brocchi S et al (2018) New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 67:1674\u20131682","journal-title":"Gut"},{"key":"9000_CR8","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.2018181494","volume":"289","author":"V Chernyak","year":"2018","unstructured":"Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver Imaging Reporting and Data System (LI-RADS) Version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816\u2013830","journal-title":"Radiology"},{"key":"9000_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EAFTSOT Liver","year":"2018","unstructured":"Liver EAFTSOT (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182\u2013236","journal-title":"J Hepatol"},{"key":"9000_CR10","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1007\/s00330-019-06499-9","volume":"30","author":"TH Kim","year":"2020","unstructured":"Kim TH, Woo S, Han S, Suh CH, Lee DH, Lee JM (2020) Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis. Eur Radiol 30:1624\u20131633","journal-title":"Eur Radiol"},{"key":"9000_CR11","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2214\/AJR.16.17711","volume":"209","author":"CH Suh","year":"2017","unstructured":"Suh CH, Kim KW, Pyo J, Lee J, Kim SY, Park SH (2017) Hypervascular transformation of hypovascular hypointense nodules in the hepatobiliary phase of gadoxetic acid-enhanced MRI: a systematic review and meta-analysis. AJR Am J Roentgenol 209:781\u2013789","journal-title":"AJR Am J Roentgenol"},{"key":"9000_CR12","doi-asserted-by":"crossref","unstructured":"Ricke J, Steffen IG, Bargellini I et al (2020) Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Rep 100173","DOI":"10.1016\/j.jhepr.2020.100173"},{"key":"9000_CR13","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Kl\u00fcmpen HJ, Amthauer H et al (2019) Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 71:1164\u20131174","journal-title":"J Hepatol"},{"key":"9000_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/hep.20728","volume":"42","author":"L Bolondi","year":"2005","unstructured":"Bolondi L, Gaiani S, Celli N et al (2005) Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 42:27\u201334","journal-title":"Hepatology"},{"key":"9000_CR15","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jhep.2013.01.030","volume":"58","author":"H Toyoda","year":"2013","unstructured":"Toyoda H, Kumada T, Tada T et al (2013) Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. J Hepatol 58:1174\u20131180","journal-title":"J Hepatol"},{"key":"9000_CR16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1148\/radiol.12112677","volume":"266","author":"T Hyodo","year":"2013","unstructured":"Hyodo T, Murakami T, Imai Y et al (2013) Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology 266:480\u2013490","journal-title":"Radiology"},{"key":"9000_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1148\/radiol.2019182867","volume":"292","author":"SM Lee","year":"2019","unstructured":"Lee SM, Lee JM, Ahn SJ, Kang H-J, Yang HK, Yoon JH (2019) LI-RADS Version 2017 versus Version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium\u2013enhanced MRI. Radiology 292:655\u2013663","journal-title":"Radiology"},{"key":"9000_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1148\/radiology.183.3.1316622","volume":"183","author":"M Kadoya","year":"1992","unstructured":"Kadoya M, Matsui O, Takashima T, Nonomura A (1992) Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 183:819\u2013825","journal-title":"Radiology"},{"key":"9000_CR19","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1053\/j.gastro.2004.09.028","volume":"127","author":"B Taouli","year":"2004","unstructured":"Taouli B, Losada M, Holland A, Krinsky G (2004) Magnetic resonance imaging of hepatocellular carcinoma. Gastroenterology 127:S144\u2013S152","journal-title":"Gastroenterology"},{"key":"9000_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1148\/radiology.210.1.r99ja4181","volume":"210","author":"M Ebara","year":"1999","unstructured":"Ebara M, Fukuda H, Kojima Y et al (1999) Small hepatocellular carcinoma: relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma. Radiology 210:81\u201388","journal-title":"Radiology"},{"key":"9000_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13550-021-00791-w","volume":"11","author":"O \u00d6cal","year":"2021","unstructured":"\u00d6cal O, Kup\u010dinskas J, Morkunas E et al (2021) Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. EJNMMI Res 11:51","journal-title":"EJNMMI Res"},{"key":"9000_CR22","doi-asserted-by":"publisher","unstructured":"\u00d6cal O, Sch\u00fctte K, Kup\u010dinskas J et al (2021) Baseline interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. J Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-021-03627-1","DOI":"10.1007\/s00432-021-03627-1"},{"key":"9000_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00270-017-1622-4","volume":"40","author":"M Seidensticker","year":"2017","unstructured":"Seidensticker M, Powerski M, Seidensticker R et al (2017) Cytokines and (90)Y-radioembolization: relation to liver function and overall survival. Cardiovasc Intervent Radiol 40:1185\u20131195","journal-title":"Cardiovasc Intervent Radiol"},{"key":"9000_CR24","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/hep.24644","volume":"54","author":"M Iavarone","year":"2011","unstructured":"Iavarone M, Cabibbo G, Piscaglia F et al (2011) Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54:2055\u20132063","journal-title":"Hepatology"},{"key":"9000_CR25","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1007\/s00330-020-07171-3","volume":"31","author":"S Colagrande","year":"2021","unstructured":"Colagrande S, Calistri L, Campani C et al (2021) CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib. Eur Radiol 31:1608\u20131619","journal-title":"Eur Radiol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-09000-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-022-09000-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-09000-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T12:14:16Z","timestamp":1671106456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-022-09000-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["9000"],"URL":"http:\/\/dx.doi.org\/10.1007\/s00330-022-09000-1","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":["Radiology, Nuclear Medicine and imaging","General Medicine"],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"20 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Max Seidensticker.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"Maciej Pech: grants: Sirtex, Bayer; personal fees: SirtexPeter Malfertheiner: grants: Bayer, SirtexJens Ricke: grants: Sirtex, Bayer; personal fees: Sirtex, BayerMax Seidensticker: personal fees: Bayer, Sirtex","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors (O.\u00d6.) has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The main results of the clinical trial have been previously reported in <i>Ricke J Hepatology 2019.<\/i>","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"value":"\u2022 retrospective\u2022 diagnostic or prognostic study\u2022 multicenter study","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}} |